Relative efficacy of oral cancer therapy for Medicare beneficiaries versus currently covered therapy: part 2, imatinib for gastrointestinal stromal tumors (GIST)
Abernethy A P, McCrory D C
Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
Citation
Abernethy A P, McCrory D C. Relative efficacy of oral cancer therapy for Medicare beneficiaries versus currently covered therapy: part 2, imatinib for gastrointestinal stromal tumors (GIST) Rockville: Agency for Healthcare Research and Quality (AHRQ). Technology Assessment. 2005
Authors' objectives
The aim of this review is to report on the relative efficacy of oral cancer therapy for Medicare beneficiaries versus currently covered therapy, in particular on imatinib for gastrointestinal stromal tumors (GIST).